-->

PPIs and Heart Health: What the Cardiovascular Research Shows

Anatomical heart model beside several amber pill bottles on a white counter in a clinic exam room

PPIs and Heart Health: What the Cardiovascular Research Shows

A Stanford-led team mined clinical records on 2.9 million people and found that patients with reflux who took proton pump inhibitors (PPIs) had a 1.16-fold higher association with heart attack. A separate Taiwanese study in the International Journal of Cardiology found a 1.58-fold higher risk over 120 days of follow-up, though the authors estimated that about 4,357 people would need to take a PPI for one extra heart attack to occur.

These are associations from observational studies, not proof that PPIs cause heart attacks. Lab research has also suggested a possible biological mechanism. If you take omeprazole, pantoprazole, esomeprazole, or another PPI daily, the cardiovascular research is worth discussing with your doctor. Do not stop a prescribed PPI on your own.

What the Research Shows

The Stanford Data-Mining Study

In 2015, Shah and colleagues published a study in PLOS ONE that searched more than 16 million clinical documents covering 2.9 million people. Patients with gastroesophageal reflux disease (GERD) who took PPIs had a 1.16-fold higher association with myocardial infarction (heart attack). In a smaller prospective cohort, PPI use was associated with about twice the risk of cardiovascular death. The association held regardless of clopidogrel use, and H2 blockers were not associated with higher cardiovascular risk.

The Taiwan Cohort Study

Shih and colleagues published a study in the International Journal of Cardiology in 2014 using Taiwan's national health insurance database. They compared 126,367 PPI users with 126,367 matched non-users who had no prior heart attack. Over 120 days, PPI use was associated with a 1.58-fold higher risk of heart attack. The authors concluded that PPIs may be independently associated with heart attack risk, but that the benefits of PPIs may greatly outweigh this risk, with a number needed to harm of 4,357.

The Vascular Mechanism Study

Ghebremariam and colleagues published a lab study in Circulation in 2013. In mice and in human tissue samples, PPIs raised levels of ADMA (asymmetric dimethylarginine), lowered nitric oxide, and reduced the ability of blood vessels to relax. The researchers found that PPIs bind to and block an enzyme called DDAH, which normally breaks down ADMA. They described this as a plausible mechanism and called for more clinical research. It has not been shown to cause heart attacks in people.

How the Proposed Mechanism Works

An Enzyme That Clears ADMA

ADMA is a natural byproduct of protein metabolism, and the DDAH enzyme breaks it down. ADMA blocks nitric oxide synthase, the enzyme that makes nitric oxide in blood vessel walls. Higher blood ADMA is associated with higher cardiovascular risk.

Why Nitric Oxide Matters

Nitric oxide helps blood vessels relax, helps keep platelets from sticking to vessel walls, and helps limit inflammation in the vessel lining. Lower nitric oxide is linked to stiffer arteries and the processes behind atherosclerosis. The lab findings suggest PPIs could nudge this pathway in the wrong direction, but whether that matters for heart attack risk in people is not yet known.

The Clopidogrel Question Is Separate

A second, separate concern involves clopidogrel (Plavix), an antiplatelet drug often prescribed after a heart attack or stent. Clopidogrel is activated in the liver by an enzyme called CYP2C19, and some PPIs, especially omeprazole and esomeprazole, also use that enzyme and can reduce clopidogrel's activation. US prescribing information for clopidogrel advises avoiding those two PPIs with it.

The picture is more complicated in practice. In the 2010 COGENT randomized trial, published in the New England Journal of Medicine, patients taking aspirin and clopidogrel who also took omeprazole had fewer gastrointestinal bleeds than those on placebo, and no significant difference in cardiovascular events, though the trial ended early and could not rule out a meaningful difference. Many people on clopidogrel take a PPI on purpose to protect against stomach bleeding. If you take both, ask your cardiologist which PPI, if any, is right for you, and do not stop either drug on your own.

Who May Want a Closer Look

  • People on clopidogrel after a heart attack or coronary stent
  • Anyone who has taken a PPI daily for more than a year
  • People with existing heart disease or high blood pressure
  • People with diabetes, chronic kidney disease, or who smoke
  • People whose PPI was started for a short-term reason and never stopped
  • Older adults, who are more likely to take PPIs long term and have higher baseline heart risk

What to Do

  1. Ask your doctor why you are still on the PPI. Many prescriptions begin for a short-term reason, such as H. pylori treatment or protection during NSAID use, and are never reviewed once that reason ends.
  2. If you take clopidogrel, ask your cardiologist to review your PPI. Some people need one to protect against bleeding, and the choice of PPI can matter.
  3. Ask for a regular medication review that covers long-term PPIs and your heart risk, especially if you have high blood pressure, diabetes, or a prior heart event.
  4. Do not stop a PPI on your own. Stopping suddenly can cause rebound acid that can feel worse than the original reflux. If your doctor agrees a change makes sense, follow their plan for a gradual taper. Our article on PPI rebound acid explains why.
  5. Work on the causes of your reflux. Diet changes, weight loss, meal timing, and raising the head of your bed help many people.

If you have chest pain, pressure, or tightness, especially with shortness of breath, sweating, or pain spreading to your arm, jaw, or back, call 911. Do not assume it is heartburn.

Natural Alternatives

If you and your doctor are working to reduce long-term PPI use, our guide to PPI alternatives covers the main options.

Some people use d-limonene, a compound from orange peel, for occasional heartburn. A 2007 review described two small, unpublished trials in which most people taking 1,000 mg of d-limonene reported heartburn relief within two weeks. Larger published trials are still needed. Read more in our complete guide to d-limonene for acid reflux.

Orange Burps is a d-limonene supplement that may help support occasional heartburn relief.

Frequently Asked Questions

Do PPIs cause heart attacks?
No study has proven that PPIs cause heart attacks. Large observational studies show an association, and lab studies suggest a possible mechanism through ADMA. Whether that mechanism explains the association is still being studied, and the added risk for any one person appears small.

Which PPIs are most dangerous for the heart?
Studies have not shown clear differences between PPIs for overall heart risk. The clopidogrel interaction is different: omeprazole and esomeprazole are the PPIs US prescribing information says to avoid with clopidogrel.

How long do you have to take PPIs before any heart risk appears?
This is not known. The Taiwan study looked at the first 120 days of use, and other studies looked at longer use. Short-term use for a clear reason raises less concern than open-ended daily use.

Are H2 blockers safer for the heart than PPIs?
In the Shah PLOS ONE study, H2 blockers were not associated with higher cardiovascular risk. That is one observational finding, not proof. If you are weighing an H2 blocker such as famotidine, ask your doctor whether it can control your symptoms.

Can I take PPIs if I have high blood pressure?
Many people with high blood pressure take PPIs. There is no clear evidence that PPIs raise blood pressure in people. If you have heart disease or high blood pressure and take a PPI long term, it is reasonable to review it with your doctor as part of your overall heart risk.

What is ADMA and why does it matter?
ADMA (asymmetric dimethylarginine) is a natural molecule that blocks nitric oxide production in blood vessels. Higher ADMA levels are associated with higher cardiovascular risk. In lab studies, PPIs raised ADMA by blocking the enzyme that clears it.

Should people on Plavix avoid PPIs?
Not necessarily. US prescribing information for clopidogrel advises avoiding omeprazole and esomeprazole, but many people on clopidogrel need a PPI to protect against stomach bleeding, and the COGENT trial found omeprazole reduced bleeding without a significant difference in cardiovascular events. Your cardiologist can choose the right option.

Can PPIs affect heart rhythm?
The evidence is limited. Long-term PPI use can lower magnesium in some people, and low magnesium can affect heart rhythm. If you notice palpitations or an irregular heartbeat, tell your doctor.

What should I do if I am worried about my PPI and heart risk?
Start by reviewing the reason you take a PPI with your doctor. If that reason has passed, ask whether you can lower the dose or taper. If you have heart disease, ask your cardiologist to include your PPI in your overall risk review.

Is the risk the same for over-the-counter PPIs like Prilosec OTC?
Over-the-counter PPIs contain the same drugs as prescription versions. The OTC label is for a 14-day course, and it tells people to ask a doctor before using it longer or more often. If you have been taking an OTC PPI for months, talk to your doctor.

The Bottom Line

PPIs are effective drugs for specific conditions. Large studies link them to a small rise in heart attack risk, and lab research suggests a possible mechanism, but these findings do not prove that PPIs cause heart attacks. If you have been on a PPI for more than a year without a review, the research is a reasonable reason to ask your doctor for one.

References

This article is for general information and is not medical advice. Talk to your doctor before starting, changing or stopping any medication.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Get a natural treatment for heartburn and acid reflux!

top